

ABSTRACT

In a method for therapeutic treatment of humans and other mammals, the therapeutic composition includes a fusogenic encapsulation vesicle and an activation agent such as an organic nanotube or α -DL peptide enclosed in the encapsulation vesicle. The activation agent is maintained in an inactivated form and becomes activated by an activation condition.